Trisha Suppes

List of Publications by Year
in descending order

63 papers	2,615 citations	257450 24 h-index	197818 49 g-index
66 all docs	66 docs citations	66 times ranked	3111 citing authors

#	Article	IF	Citations
1	Chronbiologically-based sub-groups in bipolar I disorder: A latent profile analysis. Journal of Affective Disorders, 2022, 299, 691-697.	4.1	2
2	Repetitive Transcranial Magnetic Stimulation as a Treatment for Veterans with Cognitive Impairment and Multiple Comorbidities. Journal of Alzheimer's Disease, 2022, 85, 1593-1600.	2.6	1
3	Effect of Pharmacogenomic Testing for Drug-Gene Interactions on Medication Selection and Remission of Symptoms in Major Depressive Disorder. JAMA - Journal of the American Medical Association, 2022, 328, 151.	7.4	55
4	A clinical approach to treatment resistance in depressed patients: What to do when the usual treatments don't work well enough?. World Journal of Biological Psychiatry, 2021, 22, 483-494.	2.6	32
5	Understanding mechanisms of integrated behavioral therapy for co-occurring obesity and depression in primary care: a mediation analysis in the RAINBOW trial. Translational Behavioral Medicine, 2021, 11, 382-392.	2.4	11
6	Exploring brain insulin resistance in adults with bipolar depression using extracellular vesicles of neuronal origin. Journal of Psychiatric Research, 2021, 133, 82-92.	3.1	27
7	The factor structure of depressive symptoms in patients with obesity enrolled in the RAINBOW clinical trial. Journal of Affective Disorders, 2021, 281, 367-375.	4.1	2
8	Effects of infliximab on brain neurochemistry of adults with bipolar depression. Journal of Affective Disorders, 2021, 281, 61-66.	4.1	7
9	Peripheral inflammatory biomarkers define biotypes of bipolar depression. Molecular Psychiatry, 2021, 26, 3395-3406.	7.9	19
10	25 Years of the International Bipolar Collaborative Network (BCN). International Journal of Bipolar Disorders, 2021, 9, 13.	2.2	8
11	Impact of modification to DSM-5 criterion A for hypomania/mania in newly diagnosed bipolar patients: findings from the prospective BIO study. International Journal of Bipolar Disorders, 2021, 9, 14.	2.2	4
12	Problem-solving therapy–induced amygdala engagement mediates lifestyle behavior change in obesity with comorbid depression: a randomized proof-of-mechanism trial. American Journal of Clinical Nutrition, 2021, 114, 2060-2073.	4.7	7
13	Mania and bipolar depression: complementing not opposing poles—a post-hoc analysis of mixed features in manic and hypomanic episodes. International Journal of Bipolar Disorders, 2021, 9, 36.	2.2	2
14	More assortative mating in US compared to European parents and spouses of patients with bipolar disorder: implications for psychiatric illness in the offspring. European Archives of Psychiatry and Clinical Neuroscience, 2020, 270, 237-245.	3.2	4
15	Cariprazine efficacy in bipolar I depression with and without concurrent manic symptoms: post hoc analysis of 3 randomized, placebo-controlled studies. CNS Spectrums, 2020, 25, 502-510.	1.2	178
16	A pooled post hoc analysis evaluating the safety and tolerability of cariprazine in bipolar depression. Journal of Affective Disorders, 2020, 263, 386-395.	4.1	18
17	Double jeopardy in the United States: Early onset bipolar disorder and treatment delay. Psychiatry Research, 2020, 292, 113274.	3.3	15
18	Attitudes on pharmacogenetic testing in psychiatric patients with treatment-resistant depression. Depression and Anxiety, 2020, 37, 842-850.	4.1	7

#	Article	IF	Citations
19	Leptin mediates improvements in cognitive function following treatment with infliximab in adults with bipolar depression. Psychoneuroendocrinology, 2020, 120, 104779.	2.7	11
20	Extracellular Vesicle Biomarkers Reveal Inhibition of Neuroinflammation by Infliximab in Association with Antidepressant Response in Adults with Bipolar Depression. Cells, 2020, 9, 895.	4.1	36
21	Efficacy of adjunctive infliximab vs. placebo in the treatment of anhedonia in bipolar I/II depression. Brain, Behavior, and Immunity, 2020, 88, 631-639.	4.1	44
22	Efficacy of Adjunctive Infliximab vs Placebo in the Treatment of Adults With Bipolar I/II Depression. JAMA Psychiatry, 2019, 76, 783.	11.0	135
23	A clinical model for identifying an inflammatory phenotype in mood disorders. Journal of Psychiatric Research, 2019, 113, 148-158.	3.1	16
24	Testing a clinical staging model for bipolar disorder using longitudinal life chart data. Bipolar Disorders, 2019, 21, 228-234.	1.9	23
25	Treatment-resistant and multi-therapy-resistant criteria for bipolar depression: consensus definition. British Journal of Psychiatry, 2019, 214, 27-35.	2.8	54
26	Predictors of psychosocial outcome of bipolar disorder: data from the Stanley Foundation Bipolar Network. International Journal of Bipolar Disorders, 2019, 7, 28.	2.2	17
27	Adding Increased Energy or Activity to Criterion (A) of the DSM-5 Definition of Hypomania and Mania. Journal of Clinical Psychiatry, 2019, 80, .	2.2	11
28	Evidence-Based Treatment Targets, Selection, and Strategies for Acute Manic and Mixed Episodes of Bipolar I Disorder. Journal of Clinical Psychiatry, 2019, 81, .	2.2	0
29	Bipolar disorders. Nature Reviews Disease Primers, 2018, 4, 18008.	30.5	518
30	Early Intervention in Bipolar Disorder. American Journal of Psychiatry, 2018, 175, 411-426.	7.2	218
31	The ENGAGE study: Integrating neuroimaging, virtual reality and smartphone sensing to understand self-regulation for managing depression and obesity in a precision medicine model. Behaviour Research and Therapy, 2018, 101, 58-70.	3.1	27
32	Monitoring for antidepressant-associated adverse events in the treatment of patients with major depressive disorder: An international consensus statement. World Journal of Biological Psychiatry, 2018, 19, 330-348.	2.6	32
33	Multigenerational transmission of liability to psychiatric illness in offspring of parents with bipolar disorder. Bipolar Disorders, 2018, 20, 432-440.	1.9	18
34	The association between mood state and chronobiological characteristics in bipolar I disorder: a naturalistic, variable cluster analysis-based study. International Journal of Bipolar Disorders, 2018, 6, 5.	2.2	9
35	Depression With Mixed Features in Major Depressive Disorder: A New Diagnosis or There All Along?. Journal of Clinical Psychiatry, 2018, 79, 94-95.	2.2	5
36	More childhood onset bipolar disorder in the United States than Canada or Europe: Implications for treatment and prevention. Neuroscience and Biobehavioral Reviews, 2017, 74, 204-213.	6.1	48

#	Article	IF	Citations
37	Benefits and harms of low and high second-generation antipsychotics doses for bipolar depression: A meta-analysis. Journal of Psychiatric Research, 2017, 88, 38-46.	3.1	21
38	Obesity and obstetric complications are associated with rapid-cycling in Italian patients with bipolar disorder. Journal of Affective Disorders, 2017, 208, 278-283.	4.1	20
39	Increased Activity or Energy as a Primary Criterion for the Diagnosis of Bipolar Mania in DSM-5: Findings From the STEP-BD Study. American Journal of Psychiatry, 2017, 174, 70-76.	7.2	27
40	Illnesses in siblings of US patients with bipolar disorder relate to multigenerational family history and patients severity of illness. Journal of Affective Disorders, 2017, 207, 313-319.	4.1	1
41	The relationship between self-reported borderline personality features and prospective illness course in bipolar disorder. International Journal of Bipolar Disorders, 2017, 5, 31.	2.2	19
42	Online ethics: where will the interface of mental health and the internet lead us?. International Journal of Bipolar Disorders, 2017, 5, 26.	2.2	16
43	Anxiety, irritability, and agitation as indicators of bipolar mania with depressive symptoms: a post hoc analysis of two clinical trials. International Journal of Bipolar Disorders, 2017, 5, 36.	2.2	15
44	Age of onset of bipolar disorder: Combined effect of childhood adversity and familial loading of psychiatric disorders. Journal of Psychiatric Research, 2016, 81, 63-70.	3.1	41
45	Major depressive disorder with subthreshold hypomania (mixed features): Clinical characteristics of patients entered in a multiregional, placebo-controlled study. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2016, 68, 9-14.	4.8	20
46	Mixed Depression in Bipolar Disorder: Prevalence Rate and Clinical Correlates During Naturalistic Follow-Up in the Stanley Bipolar Network. American Journal of Psychiatry, 2016, 173, 1015-1023.	7.2	52
47	Lurasidone adjunctive with lithium or valproate for bipolar depression: A placebo-controlled trial utilizing prospective and retrospective enrolment cohorts. Journal of Psychiatric Research, 2016, 78, 86-93.	3.1	48
48	Human amygdala engagement moderated by early life stress exposure is a biobehavioral target for predicting recovery on antidepressants. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 11955-11960.	7.1	50
49	Developing a clinical translational neuroscience taxonomy for anxiety and mood disorder: protocol for the baseline-follow up Research domain criteria Anxiety and Depression (â€œRADâ€) project. BMC Psychiatry, 2016, 16, 68.	2.6	33
50	Lurasidone for the Treatment of Major Depressive Disorder With Mixed Features: A Randomized, Double-Blind, Placebo-Controlled Study. American Journal of Psychiatry, 2016, 173, 400-407.	7.2	269
51	Clinical correlates of sustained response to individual drugs used in naturalistic treatment of patients with bipolar disorder. Comprehensive Psychiatry, 2016, 66, 146-156.	3.1	25
52	The Prevalence and Diagnostic Validity of Short-Duration Hypomanic Episodes and Major Depressive Episodes. Current Psychiatry Reports, 2016, 18, 27.	4.5	5
53	More illness in offspring of bipolar patients from the U.S. compared to Europe. Journal of Affective Disorders, 2016, 191, 180-186.	4.1	15
54	Toward a Valid Animal Model of Bipolar Disorder: How the Research Domain Criteria Help Bridge the Clinical-Basic Science Divide. Biological Psychiatry, 2016, 79, 62-70.	1.3	52

#	Article	IF	Citations
55	Age at Onset of Bipolar Disorder Related to Parental and Grandparental Illness Burden. Journal of Clinical Psychiatry, 2016, 77, e1309-e1315.	2.2	13
56	Further Evidence of a Cohort Effect in Bipolar Disorder. Journal of Clinical Psychiatry, 2016, 77, 1043-1049.	2.2	15
57	A Brief Commentary on the Bipolar CHOICE Study. Journal of Clinical Psychiatry, 2016, 77, e43-e44.	2.2	0
58	Patterns of response to aripiprazole, lithium, haloperidol, and placebo across factor scores of mania. International Journal of Bipolar Disorders, 2015, 3, 11.	2.2	12
59	Corrigendum to â€œEffectiveness of the Extended Release Formulation of Quetiapine as Monotherapy for the Treatment of Acute Bipolar Depressionâ€•[J. Affect. Disord. 121 (1â€"2) (2010) 106â€"115]. Journal of Affective Disorders, 2014, 168, 485-493.	4.1	14
60	Letter to the Editor in response to 2012 article by Frances and Jones. Bipolar Disorders, 2014, 16, 214-215.	1.9	3
61	First controlled treatment trial of bipolar II hypomania with mixed symptoms: Quetiapine versus placebo. Journal of Affective Disorders, 2013, 150, 37-43.	4.1	28
62	MAINTENANCE TREATMENT WITH QUETIAPINE WHEN COMBINED WITH EITHER LITHIUM OR DIVALPROEX IN BIPOLAR I DISORDER: ANALYSIS OF TWO LARGE RANDOMIZED, PLACEBO-CONTROLLED TRIALS. Depression and Anxiety, 2013, 30, 1089-1098.	4.1	31
63	Effectiveness of the extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression. Journal of Affective Disorders, 2010, 121, 106-115.	4.1	147